The Antibacterial and Anticancer Activity of Marine Actinomycete Strain HP411 Isolated in the Northern Coast of Vietnam

Authors: Huyen T. Pham, Nhue P. Nguyen, Tien Q. Phi, Phuong T. Dang, Hy G. Le

Abstract:

Since the marine environmental conditions are extremely different from the other ones, marine actinomycetes might produce novel bioactive compounds. Therefore, actinomycete strains were screened from marine water and sediment samples collected from the coastal areas of Northern Vietnam. Ninety-nine actinomycete strains were obtained on starch-casein agar media by dilution technique, only seven strains, named HP112, HP12, HP411, HPN11, HP 11, HPT13 and HPX12, showed significant antibacterial activity against both gram-positive and gram-negative bacteria (Bacillus subtilis ATCC 6633, Staphylococcus epidemidis ATCC 12228, Escherichia coli ATCC 11105). Further studies were carried out with the most active HP411 strain against Candida albicans ATCC 10231. This strain could grow rapidly on starch casein agar and other media with high salt containing 7-10% NaCl at 28-30oC. Spore-chain of HP411 showed an elongated and circular shape with 10 to 30 spores/chain. Identification of the strain was carried out by employing the taxonomical studies including the 16S rRNA sequence. Based on phylogenetic and phenotypic evidence it is proposed that HP411 to be belongs to species Streptomyces variabilis. The potent of the crude extract of fermentation broth of HP411 that are effective against wide range of pathogens: both grampositive, gram-negative and fungi. Further studies revealed that the crude extract HP411 could obtain the anticancer activity for cancer cell lines: Hep-G2 (liver cancer cell line); RD (cardiac and skeletal muscle letters cell line); FL (membrane of the uterus cancer cell line). However, the actinomycetes from marine ecosystem will be useful for the discovery of new drugs in the future.

Keywords: Marine actinomycetes, antibacterial, anticancer, Streptomyces variabilis.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1097299

References:

[1] A. L. Demain, S. Sánchez S, “Microbial drug discovery: 80 years of progress”, J. Antibiot. vol. 62, pp 5-16, 2009.
[2] J. Berdy, “Bioactive microbial metabolites”, J. Antibiotechnol. (Tokyo), vol. 58, pp. 1-26, 2005.
[3] N. S. Egorov, O. Z. Popova, M. V. Bitteeva, V. G. Bulgakova, K. Gofman “Influence of bacterial metabolites on growth and antibiotic properities of some actinomycetes”, Mikrobiologia, vol. 29, pp. 269- 275, 1960 (in Russian)
[4] H. P. Fiedler, B. Christina, T. B. Alan, C. W. Alan, G. Michael, P. Olivier, P. Carsten, H. Gerhard, H, “Marine Actinomycetes as a source of novel secondary metabolites”, Antonie Leeuwenhock, vol. 87, pp. 37- 42, 2005.
[5] B. N. Ghanem, A. S. Soraya, M. E. Zeinab, A. A. E. Gehan, “Isolation and enumeration of marine Actinomycetes from seawater and sediments in Alexandria”, J. Gen. Appl. Microbiol, vol. 46(45), pp. 105-111, 2000.
[6] H. Harada, Y. Kamei, “Selective cytotoxicity of marine algae extracts to several human leukemic cell lines”, Cytotechnology, vol. 25, pp. 213–219, 1997.
[7] M. Jennifer, “Determination of minimum inhibitory concentration”, J. Antinicrobial Chemotherapy, vol. 48, Suppl. S1, pp. 5-16, 2001.
[8] M. Kimura, “A Simple Method for Estimating Evolutionary Rates of Base Substitutions Through Comparative Studies of Nucleotide Sequences”, J. Molecular Evolution, vol. 16, pp. 111-120, 1980.
[9] K. S. Lam, “Discovery of novel metabolites from marine actinomycetes”, Curr Opin Microbiol., vol. 12, pp. 245–251, 2006.
[10] K. Likhitwitayawuid, C. K. Angerhofer, G. A. Cordell, J. M. Pezzuto, N. Ruangrungsri, “Cytotoxic and antimalarial bisbenzylisoquinoline alkaloids from Stephania erecta”, J. Natural Products, vol. 56, pp. 30- 38, 1993.
[11] T. J. Mincer, P. R. Jensen, C. A. Kauffman, W. Fenical, “Widespread and persistent populations of a major new marine actinomycte taxon in ocean sediments”, J. Appl. Environ. Microbiol., vol. 68, pp. 2005-5011, 2002.
[12] G. Mohanraj, T. Sekar, “Antagonistic activity of marine Streptomyces sp LCJ94 against the shrimp pathogens”, Annals of Biological Research, vol. 4 (4), pp. 224-227, 2013.
[13] T. F. Molinski, D. S. Dalisay, S. L. Lievens, “Drug development from marine natural products”, Nat Rev Drug Discov, vol. 8, pp. 69-85, 2009.
[14] K. Moller, T. K. Jensen, S. E. Jorsal, T. D. Leser, B. Cartensen, Veterinary Microbiology, vol. 62, pp. 59–72, 1998.
[15] M. Nakagawas, Y. Hayakawa, K. Adachi, H. Seto, “A new depsipeptide antibiotic, variapeptin” Agric. Biol. Chem., vol. 54(3), pp. 791-794, 1990.
[16] D. J. Newman, G. M. Cragg, “Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010”, J. Nat. Prod., vol. 75(3), pp. 311–335, 2012.
[17] C. Olano, C. Méndez, J. A. Salas, “Antitumor compounds from actinomycetes: from gene clusters to new derivatives by combinatorial biosynthesis”, J. Nat. Prod. Rep., vol. 26, pp. 628–660, 2009.
[18] N. Saitou, M. Nei, “The Neighbor-joining Method: A New Method for Reconstructing Phylogenetic Trees, Mol. Biol. Evol., 4: 406-425, 1987.
[19] E. B. Shirling, D. Gottlieb, “Methods for Characterization of Streptomyces species” Intern. J. Systematic Bacteriology, vol. 16 (3), pp. 313-340, 1966.
[20] H. D. Tresner, E. J. Backus, “System of color whells for Streptomycete taxonomy” Appl. Microbiol., vol. 11, pp. 335-338, 1963.
[21] S. T. Williams, M. Goodfellow, G. Alderson, “Genus Streptomyces”. In: Bergey's Manual of Systematic Bacteriology, (S.T. Williams; M. E. Sharpe; J. Holt, Edts.) Baltimore, Williams and Wilkins. vol. 4, pp. 2452-2468, 1989.